Clinical Trials Arena on MSN14h
Regeneron’s macular oedema therapy shows promise in Phase III trialIn the trial, subjects treated with the Eylea HD 8mg injection every eight weeks showed non-inferior visual acuity gains.
Older women could be vulnerable to harmful inflammation from new gene therapies to treat incurable eye diseases, new research has found.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback